McKesson at Morgan Stanley conference: outlook rises on oncology push

McKesson announced a stronger earnings outlook at the Morgan Stanley 24th Annual Global Healthcare Conference, with guidance for full-year 2027 adjusted earnings per share rising by $0.40 to $44.20 to $45.00. The company's oncology push, including its acquisition of Precision Medicine Group, contributed to the growth in its Oncology and Multispecialty segment, which reported the strongest top-line growth at 33% and adjusted operating profit growth at 41%.

However, McKesson also noted pressure in its Medsurg business, which grew by only 4%. The North American Pharmaceutical segment, which generates the majority of the company's revenue, reported 5% top-line growth and 19% year-over-year adjusted operating income growth. Despite these challenges, McKesson raised its full-year 2027 EPS guidance to $44.20 to $45.00, indicating a growth rate of 13% to 15%.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.